MilliporeSigma (Billerica, Mass.; www.emdgroup.com) announced the expansion of its state-of-the-art single-use current good manufacturing process (cGMP) facility with the addition of the Mobius 2000-L single-use bioreactor. With the new upstream suite at its Biodevelopment Center in France, MilliporeSigma can offer full process-line cGMP manufacturing, comprised of MilliporeSigma’s own instrumentation and products.
“Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production,” said Udit Batra, CEO, MilliporeSigma. “Our unique offering gives customers the choice to transfer their production at any stage with the confidence that we will ensure the most efficient transition into commercial manufacturing – at either an existing facility or one we help them design.”
With this increase in scale and scope, MilliporeSigma can advance clients’ recombinant products from cell-line development through to late-stage clinical production.